{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:11:34Z","timestamp":1788315094700,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi del Piemonte Orientale Amedeo Avogrado"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Inconclusive and limited results have been reported on the clinical utility of CYP2C19 genotyping in stroke\/TIA patients of non-East Asian ancestries. We herein performed an updated systematic review and meta-analysis to quantitatively estimate the association of CYP2C19 loss-of function (LOF) status with efficacy and safety of clopidogrel-based antiplatelet therapy in non-East Asian patients affected by stroke or TIA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive search was performed up to July 2023 using PubMed, Web of Knowledge, and Cochrane Library databases. The clinical outcomes investigated were stroke, composite vascular events and bleeding. Pooled estimates were calculated as risk ratios (RR) with 95% CI using the Mantel\u2013 Haenszel random-effects model. The quality of evidence was assessed using the GRADEpro tool.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total number of 1673 stroke\/TIA patients from 8 non-East Asian studies, published between 2014 and 2022, were included in the systematic review. Clopidogrel-treated carriers of CYP2C19 LOF alleles were found at increased risk of stroke compared to non-carriers (RR: 1.68, 95%CI: 1.04\u20132.71, P\u2009=\u20090.03). However, no significant association was observed with the risk of composite vascular events (RR: 1.15, 95%CI: 0.58\u20132.28, P\u2009=\u20090.69) or bleeding (RR: 0.84, 95%CI: 0.38\u20131.86, P\u2009=\u20090.67). Similarly, European ancestry patients carrying CYP2C19 LOF alleles displayed a higher risk of stroke (RR: 2.69 (1.11\u20136.51, P\u2009=\u20090.03), but not of composite vascular events or bleeding.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The present updated meta-analysis provides moderate quality evidence of association between CYP2C19 LOF alleles and an increased risk of stroke in non-East Asian patients with stroke\/TIA after receiving clopidogrel therapy. Further large pharmacogenetic studies are still warranted to corroborate these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10557-023-07534-0","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:02:56Z","timestamp":1701388976000},"page":"1397-1407","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Impact of CYP2C19 Genotype on Efficacy and Safety of Clopidogrel-based Antiplatelet Therapy in Stroke or Transient Ischemic Attack Patients: An Updated Systematic Review and Meta-analysis of Non-East Asian Studies"],"prefix":"10.1007","volume":"38","author":[{"given":"Sarah","family":"Cargnin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4909-1121","authenticated-orcid":false,"given":"Salvatore","family":"Terrazzino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,1]]},"reference":[{"key":"7534_CR1","doi-asserted-by":"crossref","unstructured":"GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2021; 20:795\u2013820.","DOI":"10.1016\/S1474-4422(21)00252-0"},{"key":"7534_CR2","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1177\/17474930211065917","volume":"17","author":"VL Feigin","year":"2022","unstructured":"Feigin VL, Brainin M, Norrving B, et al. World Stroke Organization (WSO): global Stroke fact sheet 2022. Int J Stroke. 2022;17:18\u201329.","journal-title":"Int J Stroke"},{"key":"7534_CR3","unstructured":"Donkor ES. Stroke in the 21st Century: a snapshot of the Burden, Epidemiology, and Quality of Life. Stroke Res Treat. 2018;3238165."},{"key":"7534_CR4","doi-asserted-by":"crossref","unstructured":"Easton JD, Saver JL, Albers GW, healthcare professionals from the American Heart Association\/American Stroke Association Stroke Council. Definition and evaluation of transient ischemic attack: a scientific statement for ; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke. 2009; 40:2276\u201393.","DOI":"10.1161\/STROKEAHA.108.192218"},{"key":"7534_CR5","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1212\/01.WNL.0000152985.32732.EE","volume":"64","author":"PM Rothwell","year":"2005","unstructured":"Rothwell PM, Warlow CP. Timing of TIAs preceding Stroke: time window for prevention is very short. Neurology. 2005;64:817\u201320.","journal-title":"Neurology"},{"key":"7534_CR6","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","volume":"52","author":"DO Kleindorfer","year":"2021","unstructured":"Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the Prevention of Stroke in patients with Stroke and transient ischemic Attack: a Guideline from the American Heart Association\/American Stroke Association. Stroke. 2021;52:e364\u2013e467.","journal-title":"Stroke"},{"key":"7534_CR7","doi-asserted-by":"publisher","first-page":"I","DOI":"10.1177\/23969873221100032","volume":"7","author":"J Dawson","year":"2022","unstructured":"Dawson J, B\u00e9jot Y, Christensen LM, et al. European Stroke Organisation (ESO) guideline on pharmacological interventions for long-term secondary prevention after ischaemic Stroke or transient ischaemic Attack. Eur Stroke J. 2022;7:I\u2013II.","journal-title":"Eur Stroke J"},{"key":"7534_CR8","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1017\/cjn.2021.127","volume":"49","author":"DJ Gladstone","year":"2022","unstructured":"Gladstone DJ, Lindsay MP, Douketis J, et al. Canadian Stroke best practice recommendations: secondary Prevention of Stroke Update 2020. Can J Neurol Sci. 2022;49:315\u201337.","journal-title":"Can J Neurol Sci"},{"key":"7534_CR9","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.ncl.2014.12.007","volume":"33","author":"S John","year":"2015","unstructured":"John S, Katzan I. Recurrent Stroke while on Antiplatelet Therapy. Neurol Clin. 2015;33:475\u201389.","journal-title":"Neurol Clin"},{"key":"7534_CR10","first-page":"711","volume":"116","author":"JT Stahmeyer","year":"2019","unstructured":"Stahmeyer JT, Stubenrauch S, Geyer S, Weissenborn K, Eberhard S. The frequency and timing of recurrent Stroke: An Analysis of Routine Health Insurance Data. Dtsch Arztebl Int. 2019;116:711\u201317.","journal-title":"Dtsch Arztebl Int"},{"key":"7534_CR11","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1136\/svn-2021-001166","volume":"7","author":"J Shah","year":"2022","unstructured":"Shah J, Liu S, Yu W. Contemporary antiplatelet therapy for secondary Stroke prevention: a narrative review of current literature and guidelines. Stroke Vasc Neurol. 2022;7:406\u201314.","journal-title":"Stroke Vasc Neurol"},{"key":"7534_CR12","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1002\/cpt.2526","volume":"112","author":"CR Lee","year":"2022","unstructured":"Lee CR, Luzum JA, Sangkuhl K, et al. Clinical pharmacogenetics implementation Consortium Guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update. Clin Pharmacol Ther. 2022;112:959\u201367.","journal-title":"Clin Pharmacol Ther"},{"key":"7534_CR13","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/FPC.0b013e3283385420","volume":"20","author":"K Sangkuhl","year":"2010","unstructured":"Sangkuhl K, Klein TE, Altman RB. Clopidogrel pathway. Pharmacogenet Genomics. 2010;20:463\u20135.","journal-title":"Pharmacogenet Genomics"},{"key":"7534_CR14","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1002\/jcph.769","volume":"56","author":"NF Ford","year":"2016","unstructured":"Ford NF. The metabolism of Clopidogrel: CYP2C19 is a minor pathway. J Clin Pharmacol. 2016;56:1474\u201383.","journal-title":"J Clin Pharmacol"},{"key":"7534_CR15","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/clpt.2008.20","volume":"84","author":"KA Kim","year":"2008","unstructured":"Kim KA, Park PW, Hong SJ, Park JY. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther. 2008;84:236\u201342.","journal-title":"Clin Pharmacol Ther"},{"key":"7534_CR16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1161\/CIRCULATIONAHA.116.024913","volume":"135","author":"Y Pan","year":"2017","unstructured":"Pan Y, Chen W, Xu Y, et al. Genetic polymorphisms and Clopidogrel Efficacy for Acute ischemic Stroke or transient ischemic Attack: a systematic review and Meta-analysis. Circulation. 2017;135:21\u201333.","journal-title":"Circulation"},{"key":"7534_CR17","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.06.008","volume":"23","author":"I Spokoyny","year":"2014","unstructured":"Spokoyny I, Barazangi N, Jaramillo V, et al. Reduced clopidogrel metabolism in a multiethnic population: prevalence and rates of recurrent cerebrovascular events. J Stroke Cerebrovasc Dis. 2014;23:694\u20138.","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"7534_CR18","doi-asserted-by":"publisher","first-page":"e001652","DOI":"10.1161\/JAHA.114.001652","volume":"4","author":"CW McDonough","year":"2015","unstructured":"McDonough CW, McClure LA, Mitchell BD, et al. CYP2C19 metabolizer status and clopidogrel efficacy in the secondary Prevention of small subcortical strokes (SPS3) study. J Am Heart Assoc. 2015;4:e001652.","journal-title":"J Am Heart Assoc"},{"key":"7534_CR19","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.3171\/2015.6.JNS15795","volume":"124","author":"BL Hoh","year":"2016","unstructured":"Hoh BL, Gong Y, McDonough CW, et al. CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic Disease. J Neurosurg. 2016;124:1746\u201351.","journal-title":"J Neurosurg"},{"key":"7534_CR20","doi-asserted-by":"crossref","unstructured":"Yan Y, Hao R, Zhao X et al. Relationship between CYP2C19*2, *3 gene polymorphism and the recurrence in ischemic Stroke patients treated with clopidogrel in China: a meta-analysis. J Stroke Cerebrovasc 2022; Dis 31(11):106798.","DOI":"10.1016\/j.jstrokecerebrovasdis.2022.106798"},{"key":"7534_CR21","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1080\/17512433.2022.2108401","volume":"15","author":"JH McDermott","year":"2022","unstructured":"McDermott JH, Leach M, Sen D, et al. The role of CYP2C19 genotyping to guide antiplatelet therapy following ischemic Stroke or transient ischemic Attack. Expert Rev Clin Pharmacol. 2022;15:811\u201325.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"7534_CR22","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"7534_CR23","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1161\/01.STR.24.1.35","volume":"24","author":"HP Adams Jr","year":"1993","unstructured":"Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic Stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35\u201341.","journal-title":"Stroke"},{"key":"7534_CR24","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/jrsm.12","volume":"1","author":"M Borenstein","year":"2010","unstructured":"Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2010;1:97\u2013111.","journal-title":"Res Synth Methods"},{"key":"7534_CR25","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2478\/bjmg-2014-0072","volume":"17","author":"HM Sen","year":"2015","unstructured":"Sen HM, Silan F, Silan C, Degirmenci Y, Ozisik Kamaran HI. Effects of CYP2C19 and P2Y12 gene polymorphisms on clinical results of patients using clopidogrel after Acute Ischemic Cerebrovascular Disease. Balkan J Med Genet. 2015;17:37\u201341.","journal-title":"Balkan J Med Genet"},{"key":"7534_CR26","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/cpt.780","volume":"103","author":"A Tornio","year":"2018","unstructured":"Tornio A, Flynn R, Morant S, et al. Investigating Real-World Clopidogrel Pharmacogenetics in Stroke using a Bioresource Linked to Electronic Medical records. Clin Pharmacol Ther. 2018;103:281\u20136.","journal-title":"Clin Pharmacol Ther"},{"key":"7534_CR27","doi-asserted-by":"publisher","first-page":"e202","DOI":"10.1097\/MJT.0000000000000416","volume":"25","author":"A Tomek","year":"2018","unstructured":"Tomek A, Mat\u02bco\u0161ka V, Fr\u00fddmanov\u00e1 A, et al. Impact of CYP2C19 polymorphisms on clinical outcomes and antiplatelet potency of Clopidogrel in caucasian poststroke survivors. Am J Ther. 2018;25:e202\u201312.","journal-title":"Am J Ther"},{"key":"7534_CR28","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1161\/STROKEAHA.119.028713","volume":"51","author":"JF Meschia","year":"2020","unstructured":"Meschia JF, Walton RL, Farrugia LP, et al. Efficacy of Clopidogrel for Prevention of Stroke based on CYP2C19 allele Status in the POINT trial. Stroke. 2020;51:2058\u201365.","journal-title":"Stroke"},{"key":"7534_CR29","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1111\/bcp.15282","volume":"88","author":"C Minderhoud","year":"2022","unstructured":"Minderhoud C, Otten LS, Hilkens PHE, van den Broek MPH, Harmsze AM. Increased frequency of CYP2C19 loss-of-function alleles in clopidogrel-treated patients with recurrent cerebral ischemia. Br J Clin Pharmacol. 2022;88:3335\u201340.","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"7534_CR30","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","volume":"141","author":"SS Virani","year":"2020","unstructured":"Virani SS, Alonso A, Benjamin EJ, et al. Heart Disease and Stroke Statistics-2020 update: a Report from the American Heart Association. Circulation. 2020;141(9):e139\u2013e596.","journal-title":"Circulation"},{"key":"7534_CR31","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1161\/STROKEAHA.120.029606","volume":"51","author":"HA Wafa","year":"2020","unstructured":"Wafa HA, Wolfe CDA, Emmett E, et al. Burden of Stroke in Europe: thirty-year projections of incidence, prevalence, deaths, and disability-adjusted life years. Stroke. 2020;51:2418\u201327.","journal-title":"Stroke"},{"key":"7534_CR32","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","volume":"396","author":"GBD 2019 Diseases and Injuries Collaborators","year":"2020","unstructured":"GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 Diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the global burden of Disease Study 2019. Lancet. 2020;396:1204\u201322.","journal-title":"Lancet"},{"key":"7534_CR33","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S0072-9752(08)94063-X","volume":"94","author":"PB Gorelick","year":"2009","unstructured":"Gorelick PB. The future of Stroke prevention by risk factor modification. Handb Clin Neurol. 2009;94:1261\u201376.","journal-title":"Handb Clin Neurol"},{"key":"7534_CR34","unstructured":"Royal Dutch Pharmacists Association (KNMP). Dutch Pharmacogenetics Working Group (DPWG). Pharmacogenetic Guidelines, Netherlands. Clopidogrel \u2013 CYP2C19, https:\/\/www.knmp.nl\/dossiers\/farmacogenetica (Accessed 1st August 2023)."},{"key":"7534_CR35","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1161\/STROKEAHA.110.594069","volume":"41","author":"CD Anderson","year":"2010","unstructured":"Anderson CD, Biffi A, Greenberg SM, Rosand J. Personalized approaches to clopidogrel therapy: are we there yet? Stroke. 2010;41:2997\u20133002.","journal-title":"Stroke"},{"key":"7534_CR36","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.ahj.2012.12.024","volume":"165","author":"KP Bliden","year":"2013","unstructured":"Bliden KP, Baker BA, Nolin TD, et al. Thienopyridine efficacy and cigarette Smoking status. Am Heart J. 2013;165:693\u2013703.","journal-title":"Am Heart J"},{"key":"7534_CR37","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1136\/heartjnl-2013-304138","volume":"100","author":"ZG Zhao","year":"2014","unstructured":"Zhao ZG, Chen M, Peng Y, et al. The impact of Smoking on clinical efficacy and pharmacodynamic effects of clopidogrel: a systematic review and meta-analysis. Heart. 2014;100:192\u20139.","journal-title":"Heart"},{"key":"7534_CR38","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.jcin.2020.01.226","volume":"13","author":"DJ Angiolillo","year":"2020","unstructured":"Angiolillo DJ, Capodanno D, Danchin N, et al. Derivation, validation, and Prognostic Utility of a prediction rule for nonresponse to Clopidogrel: the ABCD-GENE score. JACC Cardiovasc Interv. 2020;13:606\u201317.","journal-title":"JACC Cardiovasc Interv"},{"key":"7534_CR39","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1161\/STROKEAHA.120.033049","volume":"53","author":"L Dai","year":"2022","unstructured":"Dai L, Xu J, Yan H, et al. Application of Age, Body Mass Index, chronic Kidney Disease, Diabetes, and genotyping score for efficacy of Clopidogrel: secondary analysis of the CHANCE trial. Stroke. 2022;53:465\u201372.","journal-title":"Stroke"},{"key":"7534_CR40","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1001\/jama.2009.1232","volume":"302","author":"AR Shuldiner","year":"2009","unstructured":"Shuldiner AR, O\u2019Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302:849\u201357.","journal-title":"JAMA"},{"key":"7534_CR41","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1161\/CIRCINTERVENTIONS.111.962555","volume":"4","author":"YH Jeong","year":"2011","unstructured":"Jeong YH, Tantry US, Kim IS, et al. Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in east Asian acute Myocardial Infarction survivors treated with clopidogrel and aspirin. Circ Cardiovasc Interv. 2011;4:585\u201394.","journal-title":"Circ Cardiovasc Interv"},{"key":"7534_CR42","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1056\/NEJMoa1008410","volume":"363","author":"G Par\u00e9","year":"2010","unstructured":"Par\u00e9 G, Mehta SR, Yusuf S, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med. 2010;363:1704\u201314.","journal-title":"N Engl J Med"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-023-07534-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-023-07534-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-023-07534-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T21:05:08Z","timestamp":1735765508000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-023-07534-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["7534"],"URL":"https:\/\/doi.org\/10.1007\/s10557-023-07534-0","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,1]]},"assertion":[{"value":"23 November 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}